Wisconsin WEDC awards Eli Lilly up to $100M in Enterprise Zone tax credits for $4B Kenosha County expansion

Mechanism

State-level Enterprise Zone tax credit award, not a federal action. WEDC's Enterprise Zone program is a performance-based incentive: credits are earned only as the recipient hits job-creation and capital-investment milestones, and are claimed against state tax liability over the allocation period (here, through 2036) rather than paid up front. Lilly's Bristol (Kenosha County) site extends its parenteral/injectable manufacturing network — capacity relevant to its diabetes and obesity (GLP-1) product lines — and follows Lilly's 2024 acquisition of a Nexus Pharmaceuticals facility at the site. Credit split: up to $18M tied to job creation (≥700 new jobs against a ~100-person existing base) and up to $82M tied to capital investment (≥$2.2B of the $4B total project cost).

This is the same WEDC Enterprise Zone mechanism used for the Foxconn/EITMZ award (2025-11-25-us-wisconsin-wedc-foxconn-eitmz-amendment), one of several state-level reshoring incentives competing for pharmaceutical and advanced-manufacturing capex alongside federal programs (IRA, CHIPS-style credits).

Downstream implications

• Adds to the pattern of US state-level (not just federal) subsidy

competition for pharmaceutical/biotech manufacturing reshoring, parallel to the federal MFN drug-pricing push (2025-05-12-us-trump-mfn-drug-pricing-eo14273) that is separately pressuring drugmakers toward US-based production.

• Performance-based structure means the full $100M is not guaranteed —

actual fiscal cost depends on Lilly hitting the jobs/capex thresholds through 2036.

Open questions

• Whether additional Kenosha County or Wisconsin local incentives

(property tax, TIF) stack on top of the state WEDC package.

• Whether Lilly's GLP-1 (diabetes/obesity) demand growth accelerates the

capital-investment threshold being met ahead of the 2036 allocation window.